http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0207572-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2002-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d8873837baf75a97e1de71e827035e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8137a0ed50732a3162aa7153eac97a9 |
| publicationDate | 2004-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-0207572-A |
| titleOfInvention | Pharmaceutical formulation, pharmaceutical daily dose of bicalutamide administrable through the mucosa to a patient, solid dispersion of an enteric polymer, and use of an enteric polymer |
| abstract | "PHARMACEUTICAL FORMULATION, PHARMACEUTICAL DAILY OF ADMINISTRATIVE BICALUTAMIDE THROUGH MUSCLES TO A PATIENT, SOLID DISPERSION OF AN ENTERIC POLYMER". The present invention relates to a pharmaceutical formulation comprising bicalutamide and an enteric polymer having a pK-a ~ of 3 to 6. The invention also relates to a pharmaceutical daily dose of bicalutamide provided by such formulation. Additionally, the invention relates to the use of such enteric polymer in solid dispersion with bicalutamide to increase bicalutamide bioavailability; to reduce patient-to-patient variation in bicalutamide plasma concentrations; or for treating and / or reducing the risk of prostate cancer in a patient. |
| priorityDate | 2001-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419486648 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56069 |
Total number of triples: 13.